IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the ...
BOSTON -- The Pascal device for edge-to-edge mitral valve repair was as safe and effective as the MitraClip device, the pivotal CLASP IID trial showed. In a pre-specified interim analysis of the first ...
IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...
Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.
SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...
Preliminary 2-year results from the single-arm CLASP study show that mitral valve repair using the Pascal transcatheter system is associated with high rates of survival and freedom from ...
Progress continues to be made on new transcatheter devices for the treatment of severe mitral and tricuspid regurgitation, investigators reported. Several valve repair and replacement technologies, ...
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...
Please provide your email address to receive an email when new articles are posted on . At 1 year, leaflet transcatheter mitral valve repair demonstrated low rate of complications, high survival and ...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach ...
Delirium occurred in nearly 1-in-10 elderly patients after percutaneous mitral and tricuspid valve repair and signaled longer hospital stays and worse survival, a new study shows. Mortality was nearly ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...